| Type | Title | Date Released | |
|---|---|---|---|
SCHEDULE 13G/A | Sio Capital Management, LLC (Filed by) | ||
8-K | Serina Therapeutics Files Certificate of Elimination for Series A Convertible Preferred Stock | ||
8-K | Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2 | ||
EFFECT | Form EFFECT | ||
8-K | Serina Therapeutics Enters $25 Million Common Stock Purchase Agreement | ||
S-1 | Roth Principal Investments, LLC - SPA - 93% of window VWAP; after $12.5m raised, 97% for Market Open Purchases and Intraday Purchases, 95% for Pre-Market Purchases and Post-Market Purchases. 25% of regular-session volume daily, plus Pre-Market Purchases and Post-Market Purchases each ≤1m shares and 20% per window. $0.50 prior-close floor (Post-Market Purchases: same-day; overview: prior-day); 4.99% ownership cap. | ||
S-8 | Form S-8 | ||
8-K | Serina Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates | ||
10-Q | Form 10-Q | ||
4 | Simon Farrell (Reporting) | ||
3 | Simon Farrell (Reporting) | ||
8-K | Serina Therapeutics Enters into Amended and Restated Employment Agreement with CEO Steve Ledger |
